J. Jack Lee

Q: What Schools Are Affiliated With J. Jack Lee

J. Jack Lee is affiliated with the following schools: MD Anderson Cancer Center, Louisiana State University, Vanderbilt University, University of California, Los Angeles, Stanford University, Johns Hopkins University, Fudan University, University of Texas Southwestern Medical Center

J. Jack Lee's AcademicInfluence.com Rankings

J. Jack Lee

Mathematics

#5680

World Rank

#7981

Historical Rank

Statistics

#428

World Rank

#497

Historical Rank

mathematics Degrees

Download Badge

Mathematics

J. Jack Lee's Degrees

Bachelors Statistics Stanford University

Why Is J. Jack Lee Influential?

(Suggest an Edit or Addition)

(See a Problem?)

J. Jack Lee's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Exosomes Facilitate Therapeutic Targeting of Oncogenic Kras in Pancreatic Cancer (2017) (1421)
Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. (2002) (1096)
Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing (2014) (823)
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma. (2018) (816)
The BATTLE trial: personalizing therapy for lung cancer. (2011) (810)
An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance (2012) (799)
Retrovirus–mediated wild–type P53 gene transfer to tumors of patients with lung cancer. (1996) (731)
Dose Escalation Methods in Phase I Cancer Clinical Trials (2009) (690)
Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study. (2019) (641)
bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. (1995) (600)
Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. (2000) (536)
Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. (2005) (533)
Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. (1999) (507)
Clonal genetic alterations in the lungs of current and former smokers. (1997) (493)
Local Consolidative Therapy versus Maintenance Therapy/Observation for Patients with Oligometastatic Non-Small Cell Lung Cancer without Progression after Front-Line Systemic Therapy: Results of a Multi-Institutional Phase II Randomized Study (2016) (470)
Predicting cancer development in oral leukoplakia: ten years of translational research. (2000) (465)
Suppression of retinoic acid receptor-beta in premalignant oral lesions and its up-regulation by isotretinoin. (1995) (463)
Mutational Landscape of Aggressive Cutaneous Squamous Cell Carcinoma (2014) (450)
Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. (2001) (436)
PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. (2012) (430)
Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. (2012) (413)
Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis. (1993) (397)
Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. (2007) (387)
Mortality risk from squamous cell skin cancer. (2005) (369)
Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. (2002) (358)
Prostate cancer radiation dose response: results of the M.D. Anderson phase III randomized trial (2003) (351)
Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer. (2000) (337)
Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials. (2015) (334)
Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study (2019) (333)
Hypermethylation of the death-associated protein (DAP) kinase promoter and aggressiveness in stage I non-small-cell lung cancer. (2000) (316)
Overexpression of podoplanin in oral cancer and its association with poor clinical outcome (2006) (301)
Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16–Related Cancer: A Phase 2 Clinical Trial (2019) (296)
Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer. (2001) (294)
Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial (2019) (294)
Progress in Chemoprevention Drug Development: The Promise of Molecular Biomarkers for Prevention of Intraepithelial Neoplasia and Cancer—A Plan to Move Forward (2006) (272)
Lymph Node Metastases from Cutaneous Squamous Cell Carcinoma of the Head and Neck (2005) (267)
Adenovirus-mediated wild-type p53 gene transfer down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human colon cancer. (1998) (265)
PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials. (2013) (265)
The impact of smoking status, disease stage, and index tumor site on second primary tumor incidence and tumor recurrence in the head and neck retinoid chemoprevention trial. (2001) (253)
Association of Biomarker-Based Treatment Strategies With Response Rates and Progression-Free Survival in Refractory Malignant Neoplasms: A Meta-analysis. (2016) (239)
Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC (2018) (235)
Histopathologic Response Criteria Predict Survival of Patients with Resected Lung Cancer After Neoadjuvant Chemotherapy (2012) (231)
Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial. (2010) (229)
Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma. (2013) (226)
Randomized placebo-controlled trial of isotretinoin in chemoprevention of bronchial squamous metaplasia. (1994) (225)
Suppression of retinoic acid receptor beta in non-small-cell lung cancer in vivo: implications for lung cancer development. (1997) (221)
Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. (2003) (220)
Phase II Randomized, Placebo-Controlled Trial of Green Tea Extract in Patients with High-Risk Oral Premalignant Lesions (2009) (217)
Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors. (2014) (216)
Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial (2021) (215)
A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer. (2003) (208)
Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer. (2018) (208)
Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancy. (2008) (207)
Bayesian adaptive design for targeted therapy development in lung cancer — a step toward personalized medicine (2008) (200)
Improved sentinel lymph node localization in patients with primary melanoma with the use of radiolabeled colloid. (1998) (195)
p53 Expression: Predicting Recurrence and Second Primary Tumors in Head and Neck Squamous Cell Carcinoma (1996) (189)
Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer. (2012) (188)
PIK3CA Mutations Frequently Coexist with RAS and BRAF Mutations in Patients with Advanced Cancers (2011) (187)
Is follow-up of lung cancer patients after resection medically indicated and cost-effective? (1995) (185)
Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study. (2016) (182)
Objective Detection and Delineation of Oral Neoplasia Using Autofluorescence Imaging (2009) (180)
15-LOX-1: a novel molecular target of nonsteroidal anti-inflammatory drug-induced apoptosis in colorectal cancer cells. (2000) (177)
Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. (2006) (174)
Nuclear factor‐κB (nf‐κB) is frequently expressed in lung cancer and preneoplastic lesions (2006) (172)
Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysis. (2019) (171)
Phenotype and genotype of advanced premalignant head and neck lesions after chemopreventive therapy. (1998) (169)
Loss of Heterozygosity (LOH) Profiles—Validated Risk Predictors for Progression to Oral Cancer (2012) (166)
Expression of p53 oncoprotein in non-small-cell lung cancer: a favorable prognostic factor. (1995) (166)
Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer. (2017) (164)
Intensity-modulated proton beam therapy (IMPT) versus intensity-modulated photon therapy (IMRT) for patients with oropharynx cancer - A case matched analysis. (2016) (164)
Prospective risk-adjusted [18F]Fluorodeoxyglucose positron emission tomography and computed tomography assessment of radiation response in head and neck cancer. (2009) (161)
Immunohistochemical Expression of Estrogen and Progesterone Receptors Identifies a Subset of NSCLCs and Correlates with EGFR Mutation (2009) (160)
Progressive decrease in nuclear retinoic acid receptor beta messenger RNA level during breast carcinogenesis. (1997) (160)
Aberrant promoter methylation of multiple genes in bronchial brush samples from former cigarette smokers. (2002) (156)
Second primary tumors in patients with upper aerodigestive tract cancers: joint effects of smoking and alcohol (United States) (2003) (152)
Phase I Clinical Trial of Systemically Administered TUSC2(FUS1)-Nanoparticles Mediating Functional Gene Transfer in Humans (2012) (151)
Aurora-A/STK15 T+91A is a general low penetrance cancer susceptibility gene: a meta-analysis of multiple cancer types. (2005) (151)
Smoking affects treatment outcome in patients with advanced nonsmall cell lung cancer (2006) (146)
Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval. (2015) (145)
A predictive probability design for phase II cancer clinical trials (2008) (141)
CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in lung adenocarcinoma. (2013) (137)
Prognostic value of bcl-2 oncoprotein expression in stage II colon carcinoma. (1995) (137)
Expression of vascular endothelial growth factor and microvessel density in head and neck tumorigenesis. (2000) (137)
TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence. (2017) (134)
Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer. (2010) (132)
Hypermethylation of the Retinoic Acid Receptor-β2 Gene in Head and Neck Carcinogenesis (2004) (132)
Interaction Index and Different Methods for Determining Drug Interaction in Combination Therapy (2007) (131)
Phase II and biologic study of interferon alfa, retinoic acid, and cisplatin in advanced squamous skin cancer. (2002) (131)
Transforming Cancer Prevention through Precision Medicine and Immune-oncology (2016) (128)
Cancer chemoprevention: progress and promise. (1998) (128)
EZH2 Protein Expression Associates with the Early Pathogenesis, Tumor Progression, and Prognosis of Non–Small Cell Lung Carcinoma (2013) (127)
Randomized phase II designs in cancer clinical trials: current status and future directions. (2005) (126)
N-(4-hydroxyphenyl)retinamide in the chemoprevention of squamous metaplasia and dysplasia of the bronchial epithelium. (2000) (125)
Longitudinal study of smoking patterns in relation to the development of smoking‐related secondary primary tumors in patients with upper aerodigestive tract malignancies (2004) (124)
Gene Expression Profiling Predicts the Development of Oral Cancer (2011) (123)
Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors (2016) (122)
Image Analysis–based Assessment of PD-L1 and Tumor-Associated Immune Cells Density Supports Distinct Intratumoral Microenvironment Groups in Non–small Cell Lung Carcinoma Patients (2016) (122)
The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer. (2016) (121)
Revisiting stage IIIB and IV non-small cell lung cancer: analysis of the surveillance, epidemiology, and end results data. (2009) (119)
Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion (2007) (118)
Intensity Modulated Proton Therapy Versus Intensity Modulated Photon Radiation Therapy for Oropharyngeal Cancer: First Comparative Results of Patient-Reported Outcomes. (2016) (118)
Relationship Between Tumor Size and Survival in Non–Small-Cell Lung Cancer (NSCLC): An Analysis of the Surveillance, Epidemiology, and End Results (SEER) Registry (2015) (118)
Akt activation correlates with adverse outcome in tongue cancer (2005) (118)
ETS2 Mediated Tumor Suppressive Function and MET Oncogene Inhibition in Human Non–Small Cell Lung Cancer (2013) (117)
The risk of second primary tumors after resection of stage I nonsmall cell lung cancer. (2003) (117)
The influence of resection and aneuploidy on mortality in oral leukoplakia. (2004) (117)
Differential expression of E-cadherin and type IV collagenase genes predicts outcome in patients with stage I non-small cell lung carcinoma. (2000) (116)
Epidermal Growth Factor Receptor Expression and Gene Copy Number in the Risk of Oral Cancer (2010) (116)
Heterogeneous antibodies against SARS-CoV-2 spike receptor binding domain and nucleocapsid with implications for COVID-19 immunity (2020) (115)
Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy. (1996) (114)
Genomic heterogeneity of multiple synchronous lung cancer (2016) (114)
Phase I Oncology Studies: Evidence That in the Era of Targeted Therapies Patients on Lower Doses Do Not Fare Worse (2010) (112)
Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma. (1998) (112)
Increased epidermal growth factor receptor expression in metaplastic bronchial epithelium. (1996) (111)
Immunohistochemical Expression of Basic Fibroblast Growth Factor and Fibroblast Growth Factor Receptors 1 and 2 in the Pathogenesis of Lung Cancer (2008) (111)
Erlotinib and the Risk of Oral Cancer: The Erlotinib Prevention of Oral Cancer (EPOC) Randomized Clinical Trial. (2016) (110)
Comprehensive T cell repertoire characterization of non-small cell lung cancer (2020) (110)
Expression of hepatoma-derived growth factor is a strong prognostic predictor for patients with early-stage non-small-cell lung cancer. (2004) (109)
Identification of the retinoic acid-inducible Gprc5a as a new lung tumor suppressor gene. (2007) (108)
Genetic variation in MicroRNA genes and risk of oral premalignant lesions (2010) (105)
p53 and retinoid chemoprevention of oral carcinogenesis. (1995) (102)
Noninvasive evaluation of oral lesions using depth‐sensitive optical spectroscopy (2009) (102)
Low-dose isotretinoin versus beta-carotene to prevent oral carcinogenesis: long-term follow-up. (1997) (101)
Circulating tumor DNA analysis depicts subclonal architecture and genomic evolution of small cell lung cancer (2018) (100)
Prognostic value of size of lymph node metastases in patients with cutaneous melanoma. (1995) (100)
Bayesian adaptive randomization designs for targeted agent development (2008) (100)
Bayesian clinical trials at the University of Texas M. D. Anderson Cancer Center (2009) (100)
Accuracy of In Vivo Multimodal Optical Imaging for Detection of Oral Neoplasia (2012) (99)
Evaluation of tyrosinase mRNA as a tumor marker in the blood of melanoma patients. (1997) (99)
High Expression of Folate Receptor Alpha in Lung Cancer Correlates with Adenocarcinoma Histology and Mutation (2012) (98)
Cyclin D1 genotype, response to biochemoprevention, and progression rate to upper aerodigestive tract cancer. (2003) (98)
Effect of neoadjuvant chemotherapy on the immune microenvironment in non–small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches (2018) (98)
P53 Mutations in Advanced Cancers: Clinical Characteristics, Outcomes, and Correlation between Progression-Free Survival and Bevacizumab-Containing Therapy (2013) (97)
Randomized trial of 13-cis retinoic acid compared with retinyl palmitate with or without beta-carotene in oral premalignancy. (2009) (96)
Pilot Randomized Phase II Study of Celecoxib in Oral Premalignant Lesions (2008) (94)
Design and results of phase I cancer clinical trials: three-year experience at M.D. Anderson Cancer Center. (1996) (94)
Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with β-blockers (2017) (91)
Long-term impact of smoking on lung epithelial proliferation in current and former smokers. (2001) (91)
Nuclear factor-kappaB (NF-kappaB) is frequently expressed in lung cancer and preneoplastic lesions. (2006) (89)
Value of p16INK4a and RASSF1A Promoter Hypermethylation in Prognosis of Patients with Resectable Non–Small Cell Lung Cancer (2004) (88)
Retinoic acid receptor-beta as a prognostic indicator in stage I non-small-cell lung cancer. (2000) (88)
PIK3CA Mutations in Advanced Cancers: Characteristics and Outcomes (2012) (88)
Oral Epithelium as a Surrogate Tissue for Assessing Smoking-Induced Molecular Alterations in the Lungs (2008) (88)
IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves (2020) (87)
Randomized trial of adjuvant 13-cis-retinoic acid and interferon alfa for patients with aggressive skin squamous cell carcinoma. (2007) (86)
The incidence of second primary tumors in long-term survivors of small-cell lung cancer. (1992) (84)
DNA Repair Biomarker Profiling of Head and Neck Cancer: Ku80 Expression Predicts Locoregional Failure and Death following Radiotherapy (2011) (83)
Treatment of former smokers with 9-cis-retinoic acid reverses loss of retinoic acid receptor-beta expression in the bronchial epithelium: results from a randomized placebo-controlled trial. (2003) (82)
Phase II study of gefitinib in patients with advanced salivary gland cancers (2015) (81)
Nuclear retinoid acid receptor beta in bronchial epithelium of smokers before and during chemoprevention. (1999) (81)
Computed Tomography RECIST Assessment of Histopathologic Response and Prediction of Survival in Patients with Resectable Non–Small-Cell Lung Cancer after Neoadjuvant Chemotherapy (2013) (80)
Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer. (2020) (79)
Elevated BCRP/ABCG2 Expression Confers Acquired Resistance to Gefitinib in Wild-Type EGFR-Expressing Cells (2011) (79)
p53 expressions: predicting recurrence and second primary tumors in head and neck squamous cell carcinoma. (1996) (79)
Change in tumor size by RECIST correlates linearly with overall survival in phase I oncology studies. (2012) (77)
Histologic patterns and molecular characteristics of lung adenocarcinoma associated with clinical outcome (2012) (77)
Feasibility of Image-Guided Transthoracic Core-Needle Biopsy in the BATTLE Lung Trial (2013) (77)
A Five-Gene and Corresponding Protein Signature for Stage-I Lung Adenocarcinoma Prognosis (2010) (77)
Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations. (2016) (77)
Epidermal growth factor receptor regulates MET levels and invasiveness through hypoxia-inducible factor-1α in non-small cell lung cancer cells (2010) (76)
Tissue platinum concentration and tumor response in non-small-cell lung cancer. (2012) (75)
Erlotinib in the treatment of recurrent or metastatic cutaneous squamous cell carcinoma: A single‐arm phase 2 clinical trial (2018) (75)
Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma. (2013) (73)
Impact of Smoking Cessation on Global Gene Expression in the Bronchial Epithelium of Chronic Smokers (2005) (72)
Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial. (2015) (72)
Abnormalities of the TITF-1 Lineage-Specific Oncogene in NSCLC: Implications in Lung Cancer Pathogenesis and Prognosis (2011) (72)
Phase II study of paclitaxel, ifosfamide, and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma (2001) (71)
Decision analysis for prophylactic cranial irradiation for patients with small-cell lung cancer. (2006) (68)
TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics (2016) (67)
Nucleotide Excision Repair Pathway Genes and Oral Premalignant Lesions (2007) (65)
Cellular and humoral immune responses to adenovirus and p53 protein antigens in patients following intratumoral injection of an adenovirus vector expressing wild-type p53 (Ad-p53) (2000) (64)
Benzo[a]pyrene diol epoxide and bleomycin sensitivity and susceptibility to cancer of upper aerodigestive tract. (1998) (64)
Chromosome instability in lymphocytes: a potential indicator of predisposition to oral premalignant lesions. (2002) (64)
Chemoradiotherapy with or without AE-941 in stage III non-small cell lung cancer: a randomized phase III trial. (2010) (64)
Redesigning radiotherapy quality assurance: opportunities to develop an efficient, evidence-based system to support clinical trials--report of the National Cancer Institute Work Group on Radiotherapy Quality Assurance. (2012) (64)
Phase I/II study of docetaxel, cisplatin, and concomitant boost radiation for locally advanced squamous cell cancer of the head and neck. (2006) (63)
Unique molecular signatures as a hallmark of patients with metastatic breast cancer: Implications for current treatment paradigms (2014) (63)
Adaptive designs for identifying optimal biological dose for molecularly targeted agents (2014) (63)
Novel Susceptibility Loci for Second Primary Tumors/Recurrence in Head and Neck Cancer Patients: Large-Scale Evaluation of Genetic Variants (2009) (62)
Prognostic impact of insulin receptor expression on survival of patients with nonsmall cell lung cancer (2012) (62)
Correlates of mutagen sensitivity in patients with upper aerodigestive tract cancer. (1997) (62)
Increased VEGFR-2 gene copy is associated with chemoresistance and shorter survival in patients with non-small-cell lung carcinoma who receive adjuvant chemotherapy. (2011) (62)
GATA-6 transcriptional regulation of 15-lipoxygenase-1 during NSAID-induced apoptosis in colorectal cancer cells. (2002) (62)
Epidemiology of Head and Neck Squamous Cell Cancer Among HIV-Infected Patients (2014) (62)
Programmed Death Ligand 1 Heterogeneity and its Impact on Benefit from Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer. (2020) (61)
Biochemopreventive therapy for patients with premalignant lesions of the head and neck and p53 gene expression. (2000) (61)
A Generalized Response Surface Model with Varying Relative Potency for Assessing Drug Interaction (2006) (61)
Anti-retinoic acid (RA) antibody binding to human premalignant oral lesions, which occurs less frequently than binding to normal tissue, increases after 13-cis-RA treatment in vivo and is related to RA receptor beta expression. (1995) (60)
Worth Adapting? Revisiting the Usefulness of Outcome-Adaptive Randomization (2012) (60)
Incidence, Risk Factors, and Impact of Severe Neutropenia After Hyperthermic Intraperitoneal Mitomycin C (2009) (60)
Elevated epithelial insulin-like growth factor expression is a risk factor for lung cancer development. (2009) (59)
Galectin-1 and galectin-3 expression in human prostate tissue and prostate cancer (1999) (59)
MicroRNA-related genetic variations as predictors for risk of second primary tumor and/or recurrence in patients with early-stage head and neck cancer. (2010) (59)
bcl-2 and p53 expression in resectable pancreatic adenocarcinomas: association with clinical outcome. (1996) (58)
Cyclin D1 gene polymorphism as a risk factor for oral premalignant lesions. (2006) (58)
Relationship of P‐glycoprotein and carcinoembryonic antigen expression in human colon carcinoma to local invasion, dna ploidy, and disease relapse (1994) (57)
PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non-Small Cell Lung Cancer. (2019) (57)
ΔNp63 Overexpression, Alone and in Combination with Other Biomarkers, Predicts the Development of Oral Cancer in Patients with Leukoplakia (2009) (57)
Expression of ΔDNMT3B Variants and Its Association with Promoter Methylation of p16 and RASSF1A in Primary Non–Small Cell Lung Cancer (2006) (56)
p53 protein accumulation and genomic instability in head and neck multistep tumorigenesis. (2001) (56)
Bcl-2 and p53 expressions in invasive bladder cancers. (1998) (56)
Differential expression profiling of head and neck squamous carcinoma: significance in their phenotypic and biological classification (2002) (56)
Cost‐effectiveness of prostate cancer chemoprevention (2008) (55)
Adding Erlotinib to Chemoradiation Improves Overall Survival but not Progression-Free Survival in Stage III Non-Small-Cell Lung Cancer (2015) (55)
Comprehensive Biomarker Analysis and Final Efficacy Results of Sorafenib in the BATTLE Trial (2013) (55)
Identification and validation of differences in protein levels in normal, premalignant, and malignant lung cells and tissues using high-throughput Western Array and immunohistochemistry. (2006) (54)
Prognostic implication of microsatellite alteration profiles in early-stage non-small cell lung cancer. (2000) (54)
Agreement on Major Pathological Response in NSCLC Patients Receiving Neoadjuvant Chemotherapy. (2020) (54)
Identification of Gene Signatures and Molecular Markers for Human Lung Cancer Prognosis using an In vitro Lung Carcinogenesis System (2009) (54)
Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer (2021) (54)
Unique molecular landscapes in cancer: implications for individualized, curated drug combinations. (2014) (54)
New DNA Methylation Markers and Global DNA Hypomethylation Are Associated with Oral Cancer Development (2015) (53)
The allergy mediator histamine confers resistanceto immunotherapy in cancer patients via activationof the macrophage histamine receptor H1. (2021) (53)
Controlled multi-arm platform design using predictive probability (2018) (53)
The Prognostic and Therapeutic Role of Genomic Subtyping by Sequencing Tumor or Cell-Free DNA in Pulmonary Large-Cell Neuroendocrine Carcinoma (2019) (52)
Accrual strategies for phase I trials with delayed patient outcome. (1999) (52)
Fenretinide Activity in Retinoid-Resistant Oral Leukoplakia (2006) (51)
Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (2013) (51)
Biological Activity of Celecoxib in the Bronchial Epithelium of Current and Former Smokers (2010) (51)
CR represents an early index of potential long survival in multiple myeloma (2010) (51)
Relation between the level of lymph node metastasis and survival in locally advanced head and neck squamous cell carcinoma (2016) (51)
Micronuclei, a biomarker for chemoprevention trials: Results of a randomized study in oral pre‐malignancy (1994) (50)
Phase I trial of alpha-tocopherol effects on 13-cis-retinoic acid toxicity. (1997) (50)
The BATTLE to Personalize Lung Cancer Prevention through Reverse Migration (2011) (50)
Multiregion gene expression profiling reveals heterogeneity in molecular subtypes and immunotherapy response signatures in lung cancer (2018) (50)
JAK1/STAT3 Activation through a Proinflammatory Cytokine Pathway Leads to Resistance to Molecularly Targeted Therapy in Non–Small Cell Lung Cancer (2017) (50)
The impact of phosphorylated AMP-activated protein kinase expression on lung cancer survival. (2012) (49)
Phase I dose de-escalation trial of alpha-difluoromethylornithine in patients with grade 3 cervical intraepithelial neoplasia. (1998) (49)
The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non–Small Cell Lung Cancer (2017) (48)
Repair Capacity for UV Light–Induced DNA Damage Associated with Risk of Nonmelanoma Skin Cancer and Tumor Progression (2007) (48)
Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study. (2019) (46)
A Randomized Controlled Trial of Celecoxib to Prevent Recurrence of Nonmuscle-Invasive Bladder Cancer (2011) (46)
Selenium Accumulation in Prostate Tissue During a Randomized, Controlled Short-term Trial of l-Selenomethionine: a Southwest Oncology Group Study (2006) (46)
Genetic Variants in the PI3K/PTEN/AKT/mTOR Pathway Predict Head and Neck Cancer Patient Second Primary Tumor/Recurrence Risk and Response to Retinoid Chemoprevention (2012) (46)
Impact of Neoadjuvant Durvalumab with or without Tremelimumab on CD8+ Tumor Lymphocyte Density, Safety, and Efficacy in Patients with Oropharynx Cancer: CIAO Trial Results (2020) (46)
Comparison of p53 immunoreactivity in fresh-cut versus stored slides with and without microwave heating. (1997) (46)
Gene expression screening of salivary gland neoplasms: molecular markers of potential histogenetic and clinical significance. (2004) (45)
BOP2: Bayesian optimal design for phase II clinical trials with simple and complex endpoints (2017) (45)
Immunohistochemical and Image Analysis‐Based Study Shows That Several Immune Checkpoints are Co‐expressed in Non–Small Cell Lung Carcinoma Tumors (2018) (45)
An overview of the design and conduct of the BATTLE trials. (2015) (45)
Serum Signature of Hypoxia-Regulated Factors Is Associated with Progression after Induction Therapy in Head and Neck Squamous Cell Cancer (2010) (44)
Immune evolution from preneoplasia to invasive lung adenocarcinomas and underlying molecular features (2020) (44)
g-Protein Coupled Receptor Family C, Group 5, Member A (gprc5a) Expression Is Decreased in the Adjacent Field and Normal Bronchial Epithelia of Patients with Chronic Obstructive Pulmonary Disease and Non–Small-Cell Lung Cancer (2012) (44)
Accumulation of p53 protein and retinoic acid receptor beta in retinoid chemoprevention. (1997) (44)
VEGF/VEGFR-2 Upregulates EZH2 Expression in Lung Adenocarcinoma Cells and EZH2 Depletion Enhances the Response to Platinum-Based and VEGFR-2–Targeted Therapy (2014) (44)
Expression profiling stratifies mesothelioma tumors and signifies deregulation of spindle checkpoint pathway and microtubule network with therapeutic implications. (2014) (44)
Statistical Innovations in Cancer Research (2003) (43)
Cyclin D1 and Cancer Development in Laryngeal Premalignancy Patients (2009) (43)
Long-term results of a randomized phase III trial of TPF induction chemotherapy followed by surgery and radiation in locally advanced oral squamous cell carcinoma (2015) (43)
Epidermal growth factor receptor and K‐Ras mutations and resistance of lung cancer to insulin‐like growth factor 1 receptor tyrosine kinase inhibitors (2012) (43)
Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study (2019) (42)
One step forward, two steps back. (2014) (42)
Reducing the "risk" of chemoprevention: defining and targeting high risk--2005 AACR Cancer Research and Prevention Foundation Award Lecture. (2006) (42)
Canadian Optically-guided approach for Oral Lesions Surgical (COOLS) trial: study protocol for a randomized controlled trial (2011) (41)
Expression of Delta DNMT3B variants and its association with promoter methylation of p16 and RASSF1A in primary non-small cell lung cancer. (2006) (40)
Durable long-term remission with chemotherapy alone for stage II to IV laryngeal cancer. (2009) (40)
Receptor Tyrosine Kinase EphA5 Is a Functional Molecular Target in Human Lung Cancer* (2015) (40)
A utility‐based Bayesian optimal interval (U‐BOIN) phase I/II design to identify the optimal biological dose for targeted and immune therapies (2019) (39)
Bayesian randomized trial comparing intensity modulated radiation therapy versus passively scattered proton therapy for locally advanced non-small cell lung cancer. (2016) (39)
Confidence Intervals of Interaction Index for Assessing Multiple Drug Interaction (2009) (39)
Mutagen sensitivity as a predictor of tumor recurrence in patients with cancer of the upper aerodigestive tract. (1998) (39)
Bayesian two-step Lasso strategy for biomarker selection in personalized medicine development for time-to-event endpoints. (2013) (38)
High-Dose Fenretinide in Oral Leukoplakia (2009) (37)
Demystify statistical significance--time to move on from the p value to bayesian analysis. (2011) (37)
Next-Generation CDK2/9 Inhibitors and Anaphase Catastrophe in Lung Cancer (2017) (36)
Characterizing the Molecular Spatial and Temporal Field of Injury in Early-Stage Smoker Non–Small Cell Lung Cancer Patients after Definitive Surgery by Expression Profiling (2012) (36)
A phase 2 study of cetuximab in combination with docetaxel in chemotherapy‐refractory/resistant patients with advanced nonsmall cell lung cancer (2009) (36)
Modulation of proliferating cell nuclear antigen in the bronchial epithelium of smokers. (2001) (35)
The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma (2002) (35)
A statistical analysis of the reliability and classification error in application of the mutagen sensitivity assay. (1996) (35)
The Cost of Prostate Cancer Chemoprevention: A Decision Analysis Model (2006) (34)
Elevated Cyclin D1 Expression Is Predictive for a Benefit from TPF Induction Chemotherapy in Oral Squamous Cell Carcinoma Patients with Advanced Nodal Disease (2013) (34)
A phase I/II study combining erlotinib and dasatinib for non-small cell lung cancer. (2014) (34)
Tetranucleotide Microsatellite Instability in Surgical Margins for Prediction of Local Recurrence of Head and Neck Squamous Cell Carcinoma (2004) (34)
Immunohistochemical overexpression of platelet-derived growth factor receptor-beta (PDGFR-β) is associated with PDGFRB gene copy number gain in sarcomatoid non-small-cell lung cancer. (2011) (33)
Targeting the insulin-like growth factor receptor and Src signaling network for the treatment of non-small cell lung cancer (2015) (33)
Adaptive clinical trial designs in oncology. (2014) (32)
Expression of Interleukin-1 Receptor–Associated Kinase-1 in Non–Small Cell Lung Carcinoma and Preneoplastic Lesions (2009) (32)
Phase I and pharmacokinetic study of exatecan mesylate (DX-8951f): a novel camptothecin analog. (2001) (32)
Comprehensive Analysis of the Discordance of EGFR Mutation Status between Tumor Tissues and Matched Circulating Tumor DNA in Advanced Non–Small Cell Lung Cancer (2017) (32)
Global Assessment of Genetic Variation Influencing Response to Retinoid Chemoprevention in Head and Neck Cancer Patients (2011) (32)
Local Consolidative Therapy (LCT) Improves Overall Survival (OS) Compared to Maintenance Therapy/Observation in Oligometastatic Non-Small Cell Lung Cancer (NSCLC): Final Results of a Multicenter, Randomized, Controlled Phase 2 Trial (2018) (32)
Expression of heterogeneous nuclear ribonucleoprotein A2/B1 in bronchial epithelium of chronic smokers. (1998) (31)
CD147 and Ki-67 overexpression confers poor prognosis in squamous cell carcinoma of oral tongue: a tissue microarray study. (2015) (31)
Serum calcitonin in small cell carcinoma of the prostate. (1996) (31)
Short telomere lengths in peripheral blood leukocytes are associated with an increased risk of oral premalignant lesion and oral squamous cell carcinoma (2013) (31)
Triple-Negative Breast Cancer Patients Treated at MD Anderson Cancer Center in Phase I Trials: Improved Outcomes with Combination Chemotherapy and Targeted Agents (2014) (31)
Asian ethnicity as a predictor of response in patients with non-small-cell lung cancer treated with gefitinib on an expanded access program. (2006) (30)
The ISG15-specific protease USP18 regulates stability of PTEN (2016) (30)
Targeted Tissue and Cell‐Free Tumor DNA Sequencing of Advanced Lung Squamous‐Cell Carcinoma Reveals Clinically Significant Prevalence of Actionable Alterations (2019) (29)
Proteogenomic Analysis of Salivary Adenoid Cystic Carcinomas Defines Molecular Subtypes and Identifies Therapeutic Targets (2020) (29)
The tobacco-specific carcinogen-operated calcium channel promotes lung tumorigenesis via IGF2 exocytosis in lung epithelial cells (2016) (29)
Distinct tumor-infiltrating lymphocyte landscapes are associated with clinical outcomes in localized non-small cell lung cancer. (2021) (29)
Model-Assisted Designs for Early-Phase Clinical Trials: Simplicity Meets Superiority. (2019) (29)
Unexpected cytokines in serum of malignant melanoma patients during sequential biochemotherapy. (2000) (29)
Loss of E‐cadherin and p27 expression is associated with head and neck squamous tumorigenesis (2005) (29)
Prediction of Survival in Resected Non–Small Cell Lung Cancer Using a Protein Expression–Based Risk Model: Implications for Personalized Chemoprevention and Therapy (2013) (29)
Phase II Trials of Imatinib Mesylate and Docetaxel in Patients with Metastatic Non-small Cell Lung Cancer and Head and Neck Squamous Cell Carcinoma (2011) (28)
Increased Retinoic Acid Receptor-β4 Correlates In vivo with Reduced Retinoic Acid Receptor-β2 in Esophageal Squamous Cell Carcinoma (2005) (28)
A Semiparametric Response Surface Model for Assessing Drug Interaction (2008) (28)
In vitro protective effects of chemopreventive agents against bleomycin-induced genotoxicity in lymphoblastoid cell lines and peripheral blood lymphocytes of head and neck cancer patients. (1993) (27)
Suppressed immune microenvironment and repertoire in brain metastases from patients with resected non-small-cell lung cancer. (2019) (27)
Response rates and survival to systemic therapy after immune checkpoint inhibitor failure in recurrent/metastatic head and neck squamous cell carcinoma. (2019) (27)
Target-Based Therapeutic Matching in Early-Phase Clinical Trials in Patients with Advanced Colorectal Cancer and PIK3CA Mutations (2013) (27)
Comparison of multispectral wide-field optical imaging modalities to maximize image contrast for objective discrimination of oral neoplasia. (2010) (27)
Histone H3 messenger RNA in situ hybridization correlates with in vivo bromodeoxyuridine labeling of S-phase cells in rat colonic epithelium. (1996) (27)
Clinical Trial Characteristics and Barriers to Participant Accrual: The MD Anderson Cancer Center Experience over 30 years, a Historical Foundation for Trial Improvement (2017) (26)
Genotype-specific differences in circulating tumor DNA levels in advanced NSCLC. (2020) (26)
PEA-15 unphosphorylated at both serine 104 and serine 116 inhibits ovarian cancer cell tumorigenicity and progression through blocking β-catenin (2012) (26)
Biologic correlates of a biochemoprevention trial in advanced upper aerodigestive tract premalignant lesions. (2002) (26)
AACR White Paper: Shaping the Future of Cancer Prevention – A Roadmap for Advancing Science and Public Health (2018) (26)
Phase I trial of cisplatin, pemetrexed, and imatinib mesylate in chemonaive patients with unresectable malignant pleural mesothelioma. (2014) (26)
Genetic variations in regulator of G-protein signaling genes as susceptibility loci for second primary tumor/recurrence in head and neck squamous cell carcinoma. (2010) (25)
Genetic variations in cell‐cycle pathway and the risk of oral premalignant lesions (2008) (25)
Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer (2021) (25)
Design considerations for efficient prostate cancer chemoprevention trials. (2001) (25)
drexplorer: A tool to explore dose-response relationships and drug-drug interactions (2015) (25)
Loss of Fhit Expression in Head and Neck Squamous Cell Carcinoma and Its Potential Clinical Implication (2004) (24)
Cyclooxygenase‐2 gene polymorphisms reduce the risk of oral premalignant lesions (2009) (24)
Phase Ib Randomized, Double-Blinded, Placebo-Controlled, Dose Escalation Study of Polyphenon E in Patients with Barrett's Esophagus (2013) (24)
Comparing Intensity-Modulated Proton Therapy With Intensity-Modulated Photon Therapy for Oropharyngeal Cancer: The Journey From Clinical Trial Concept to Activation. (2018) (23)
Comparison of Bayesian Sample Size Criteria: ACC, ALC, and WOC. (2009) (23)
Breast tissue accumulation of retinamides in a randomized short-term study of fenretinide. (2003) (23)
Bayesian Two-Stage Biomarker-Based Adaptive Design for Targeted Therapy Development (2016) (23)
Membrane Carbonic Anhydrase IX Expression and Relapse Risk in Resected Stage I–II Non–Small-Cell Lung Cancer (2014) (22)
Multiomics profiling of primary lung cancers and distant metastases reveals immunosuppression as a common characteristic of tumor cells with metastatic plasticity (2020) (22)
Retinoic acid receptor beta and telomerase catalytic subunit expression in bronchial epithelium of heavy smokers. (2003) (22)
Prospective imaging assessment of mortality risk after head-and-neck radiotherapy. (2010) (22)
ISA101 and nivolumab for HPV-16+ cancer: updated clinical efficacy and immune correlates of response (2022) (22)
A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer (2015) (22)
A Systems Biology-Based Gene Expression Classifier of Glioblastoma Predicts Survival with Solid Tumors (2009) (21)
Prognostic implications of tumoral expression of insulin like growth factors 1 and 2 in patients with non-small-cell lung cancer. (2014) (21)
Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naïve study (2021) (21)
Phase 2 study of carboplatin, docetaxel, and bevacizumab as frontline treatment for advanced nonsmall‐cell lung cancer (2010) (21)
Clinical Outcomes and Biomarker Profiles of Elderly Pretreated NSCLC Patients from the BATTLE Trial (2012) (21)
Evolution of DNA methylome from precancerous lesions to invasive lung adenocarcinomas (2021) (21)
Met Receptor Tyrosine Kinase and Chemoprevention of Oral Cancer (2018) (20)
Implications of the prostate cancer prevention trial: a decision analysis model of survival outcomes. (2005) (20)
Proliferative changes in the bronchial epithelium of former smokers treated with retinoids. (2007) (19)
Smoking affects treatment outcome in patients with advanced non-small cell lung cancer. (2004) (19)
Naproxen chemoprevention promotes immune activation in Lynch syndrome colorectal mucosa (2020) (19)
Increased leukocyte mitochondrial DNA copy number is associated with oral premalignant lesions: an epidemiology study. (2014) (19)
STK11/LKB1 Mutations in NSCLC Are Associated with KEAP1/NRF2-Dependent Radiotherapy Resistance Targetable by Glutaminase Inhibition (2020) (19)
A robust two‐stage design identifying the optimal biological dose for phase I/II clinical trials (2017) (19)
Expression pattern of FGFR2, Grb2 and Plcγ1 acts as a novel prognostic marker of recurrence recurrence-free survival in lung adenocarcinoma. (2015) (19)
Phase II trial of erlotinib and radiotherapy following chemoradiotherapy for patients with stage III non-small cell lung cancer. (2011) (18)
Differential impacts of insulin-like growth factor-binding protein-3 (IGFBP-3) in epithelial IGF-induced lung cancer development. (2011) (18)
Effects of 9-cis-retinoic acid on the insulin-like growth factor axis in former smokers. (2005) (18)
Single-center phase I/Ib study of concurrent intrathecal (IT) and intravenous (IV) nivolumab (N) for metastatic melanoma (MM) patients (pts) with leptomeningeal disease (LMD). (2020) (18)
Clinical and Biomarker Outcomes of the Phase II Vandetanib Study from the BATTLE Trial (2013) (18)
Nitric oxide and neopterin levels and clinical response in stage III melanoma patients receiving concurrent biochemotherapy (1998) (18)
18F-fluorodeoxyglucose positron emission tomography correlates with tumor immunometabolic phenotypes in resected lung cancer (2020) (17)
Distinct pattern of TP53 mutations in human immunodeficiency virus–related head and neck squamous cell carcinoma (2018) (17)
Association of pathological response to neoadjuvant pembrolizumab with tumor PD-L1 expression and high disease-free survival (DFS) in patients with resectable, local-regionally advanced, head and neck squamous cell carcinoma (HNSCC). (2021) (17)
High-Risk HPV, Biomarkers, and Outcome in Matched Cohorts of Head and Neck Cancer Patients Positive and Negative for HIV (2016) (17)
A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel, and Nintedanib for Resectable Non–Small Cell Lung Cancer (2020) (17)
Phase II randomized study of biomarker-directed treatment for non-small cell lung cancer (NSCLC): The BATTLE (Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination) clinical trial program. (2009) (17)
Immune evasion in HPV− head and neck precancer–cancer transition is driven by an aneuploid switch involving chromosome 9p loss (2021) (17)
1136ONivolumab and ISA 101 HPV vaccine in incurable HPV-16+ cancer (2017) (16)
Cell kinetic analysis of intact rat colonic crypts by confocal microscopy and immunofluorescence. (1996) (16)
Cotargeting Cyclin D1 Starts a New Chapter in Lung Cancer Prevention and Therapy (2011) (16)
PIK 3 CA Mutations in Advanced Cancers : Characteristics and Outcomes (2013) (16)
Cisplatin, fluorouracil, and L-leucovorin induction chemotherapy for locally advanced head and neck cancer: the M.D. Anderson Cancer Center experience. (1997) (15)
Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function. (2016) (15)
A simulation study for comparing testing statistics in response-adaptive randomization (2010) (15)
Evolution of Genomic and T-cell Repertoire Heterogeneity of Malignant Pleural Mesothelioma Under Dasatinib Treatment (2020) (15)
Use of a Targeted Exome Next-Generation Sequencing Panel Offers Therapeutic Opportunity and Clinical Benefit in a Subset of Patients With Advanced Cancers (2019) (15)
A Randomized Multicenter Phase II Study of Docosahexaenoic Acid in Patients with a History of Breast Cancer, Premalignant Lesions, or Benign Breast Disease (2018) (15)
Weekly paclitaxel, carboplatin, cetuximab, and cetuximab, docetaxel, cisplatin, and fluorouracil, followed by local therapy in previously untreated, locally advanced head and neck squamous cell carcinoma (2019) (15)
p 53 Expression : Predicting Recurrence and Second Primary Tumors in Head and Neck Squamous Cell Carcinoma (1996) (14)
Uniform power method for sample size calculation in historical control studies with binary response. (2001) (14)
Immuno-profiling and cellular spatial analysis using five immune oncology multiplex immunofluorescence panels for paraffin tumor tissue (2021) (14)
Deletion in poly(ADP-ribose)polymerase pseudogene and lung cancer risk. (1998) (14)
Checkpoint inhibitors assessment in oropharynx cancer (CIAO): Safety and interim results. (2019) (14)
Analysis of Factors Affecting Successful Clinical Trial Enrollment in the Context of Three Prospective, Randomized, Controlled Trials. (2017) (14)
BATTLE-2 program: A biomarker-integrated targeted therapy study in previously treated patients with advanced non-small cell lung cancer (NSCLC). (2013) (14)
Commentary on Hey and Kimmelman (2015) (13)
Screening at a health fair to identify subjects for an oral leukoplakia chemoprevention trial. (2009) (13)
Phase II Clinical Trial of Neoadjuvant and Adjuvant Pembrolizumab in Resectable Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma. (2022) (13)
Single Arm, Phase II Study of Cisplatin, Docetaxel, and Erlotinib in Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinomas (2018) (13)
Anticlastogenic effects of 13-cis-retinoic acid in vitro. (1992) (13)
Value of p 16 INK 4 a and RASSF 1 A Promoter Hypermethylation in Prognosis of Patients with Resectable Non – Small Cell Lung Cancer (2004) (13)
Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC). (2018) (13)
Mortality in the Randomized, Controlled Lung Intergroup Trial of Isotretinoin (2010) (13)
Bayesian cluster hierarchical model for subgroup borrowing in the design and analysis of basket trials with binary endpoints (2020) (13)
Phase II Study of Vinorelbine and Docetaxel in the Treatment of Advanced Non–Small-Cell Lung Cancer as Frontline and Second-Line Therapy (2009) (12)
Biomarker‐Integrated Neoadjuvant Dasatinib Trial in Resectable Malignant Pleural Mesothelioma (2017) (12)
Elevated PDGFRB gene copy number gain is prognostic for improved survival outcomes in resected malignant pleural mesothelioma. (2014) (12)
Racial Differences in 20-Year Cardiovascular Mortality Risk Among Childhood and Young Adult Cancer Survivors. (2017) (12)
Bayesian hierarchical classification and information sharing for clinical trials with subgroups and binary outcomes (2018) (12)
Local consolidative therapy (LCT) to improve progression-free survival (PFS) in patients with oligometastatic non-small cell lung cancer (NSCLC) who receive induction systemic therapy (IST): Results of a multi-institutional phase II randomized study. (2016) (12)
Relationship between tumor size and survival in non-small cell lung cancer (NSCLC): An analysis of the Surveillance, Epidemiology, and End Results (SEER) registry. (2012) (12)
Interleukin-11 Receptor Is a Candidate Target for Ligand-Directed Therapy in Lung Cancer: Analysis of Clinical Samples and BMTP-11 Preclinical Activity. (2016) (12)
Identification of biomarkers of immune checkpoint blockade efficacy in recurrent or refractory solid tumor malignancies (2020) (11)
Activation of insulin-like growth factor 1 receptor in patients with non-small cell lung cancer (2015) (11)
Polyamine measurements in the uterine cervix (1997) (11)
Antitumor activity of AZ64 via G2/M arrest in non-small cell lung cancer. (2012) (11)
TITE‐BOIN12: A Bayesian phase I/II trial design to find the optimal biological dose with late‐onset toxicity and efficacy (2022) (10)
Concordance of oral HPV prevalence between patients with oropharyngeal cancer and their partners (2016) (10)
Potential Influence on Clinical Trials of Long-Term Survivors of Stage IV Non-small cell Lung Cancer (2019) (10)
The histologic phenotype of lung cancers is associated with transcriptomic features rather than genomic characteristics (2021) (10)
Phase I/II Trial of Immunotherapy With Durvalumab and Tremelimumab With Continuous or Intermittent MEK Inhibitor Selumetinib in NSCLC: Early Trial Report. (2020) (10)
Association of Driver Oncogene Variations With Outcomes in Patients With Locally Advanced Non–Small Cell Lung Cancer Treated With Chemoradiation and Consolidative Durvalumab (2022) (9)
Spatial and temporal heterogeneity of PD-L1 and its impact on benefit from immune checkpoint blockade in non-small cell lung cancer (NSCLC). (2019) (9)
Prospective study comparing outcomes in patients with advanced malignancies on molecular alteration-matched versus non-matched therapy. (2015) (9)
A pilot double-blind, randomized, placebo-controlled trial of curcumin/bioperine for lung cancer chemoprevention in patients with chronic obstructive pulmonary disease (2013) (9)
Randomized phase II trial of cixutumumab (CIX) alone or with cetuximab (CET) for refractory recurrent/metastatic squamous cancer of head and neck (R/M-SCCHN). (2013) (9)
Bayesian clinical trials at The University of Texas MD Anderson Cancer Center: An update (2019) (9)
Concomitant targeting of the mTOR/MAPK pathways: novel therapeutic strategy in subsets of RICTOR/KRAS-altered non-small cell lung cancer (2018) (9)
MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers (2022) (9)
A phase III study of Æ-941 with induction chemotherapy (IC) and concomitant chemoradiotherapy (CRT) for stage III non-small cell Lung cancer (NSCLC) (NCI T99–0046, RTOG 02–70, MDA 99–303): An interim report of toxicity and response (2005) (9)
The impact of phosphorylated AMP-activated protein kinase expression on lung cancer survival. (2012) (8)
BOIN Suite: A Software Platform to Design and Implement Novel Early-Phase Clinical Trials. (2021) (8)
Biomarker Clinical Trials in Lung Cancer: Design, Logistics, Challenges, and Practical Considerations (2018) (8)
Genomic and transcriptomic landscape of oral pre-cancers (OPCs) and risk of oral cancer (OC). (2019) (8)
A phase I/II trial combining erlotinib with gamma secretase inhibitor RO4929097 in advanced non-small cell lung cancer (NSCLC). (2013) (8)
Adaptive Clinical Trials (2014) (8)
Correlative analyses of plasma cytokine/angiogenic factor (C/AF) profile, gender and outcome in a randomized, three-arm, phase II trial of first-line vandetanib (VAN) and/or carboplatin plus paclitaxel (CP) for advanced non-small cell lung cancer (NSCLC) (2007) (8)
Modifying the Clinical Research Infrastructure at a Dedicated Clinical Trials Unit: Assessment of Trial Development, Activation, and Participant Accrual (2016) (8)
A phase I trial of intravenous therapy with tumor suppressor FUS1-nanoparticles for recurrent/metastatic lung cancer. (2016) (8)
Bayesian Adaptive Randomization and Trial Monitoring with Predictive Probability for Time-to-Event Endpoint (2018) (8)
Randomized placebo-controlled trial (RCT) of erlotinib for prevention of oral cancer (EPOC). (2014) (8)
Outcome‐adaptive randomization for a delayed outcome with a short‐term predictor: imputation‐based designs (2014) (8)
Response: Re: Dose Escalation Methods in Phase I Cancer Clinical Trials (2009) (7)
Estimation of k for the poly‐k test with application to animal carcinogenicity studies (2003) (7)
Immune profiling of oral pre-malignant lesions (OPLs): An Erlotinib Prevention of Oral Cancer (EPOC) study biobank analysis. (2017) (7)
Accelerated Approval and Breakthrough Therapy Designation: Oncology Drug Development on Speed? (2013) (7)
Efficacy of Targeted Inhibitors in Metastatic Lung Squamous Cell Carcinoma With EGFR or ALK Alterations (2021) (7)
Oncogenic enhancer of zeste homolog 2 is an actionable target in patients with non‐small cell lung cancer (2019) (7)
Multiplex Tissue Imaging Harmonization: A Multicenter Experience from CIMAC-CIDC Immuno-Oncology Biomarkers Network (2021) (7)
Incorporating historical information to improve phase I clinical trials (2021) (7)
WINTHER: An international WIN Consortium precision medicine trial using genomic and transcriptomic analysis in patients with advanced malignancies. (2018) (7)
Tissue Effects in a Randomized Controlled Trial of Short-term Finasteride in Early Prostate Cancer☆ (2016) (6)
A Phase II Trial of Ziv-Aflibercept in Patients With Advanced Pancreatic Neuroendocrine Tumors (2019) (6)
The KRAS-variant and treatment response in BATTLE-1. (2014) (6)
I-SABR phase II randomized study of nivolumab immunotherapy and stereotactic ablative radiotherapy in early stage NSCLC: Interim analysis adverse effects. (2020) (6)
Weekly paclitaxel, carboplatin, cetuximab (PCC), and cetuximab, docetaxel, cisplatin, and fluorouracil (C-TPF), followed by risk-based local therapy in previously untreated, locally advanced head and neck squamous cell carcinoma (LAHNSCC). (2015) (6)
ACCELERATED DISCOVERY 15-LOX-1: a Novel Molecular Target of Nonsteroidal Anti-inflammatory Drug-Induced Apoptosis in Colorectal Cancer Cells (2000) (6)
Randomized trial of a short course of erlotinib 150 to 300 mg daily prior to surgery for squamous cell carcinomas of the head and neck (SCCHN) in current, former, and never smokers: Objective responses and clinical outcomes. (2011) (6)
CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinoma (2021) (6)
9-cis-Retinoic Acid Treatment Increases Serum Concentrations of α-Tocopherol in Former Smokers (2005) (5)
Abstract LB-88: Gene expression signatures predictive of clinical outcome and tumor mutations in refractory NSCLC patients (pts) in the BATTLE trial (Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination) (2011) (5)
Emax model and interaction index for assessing drug interaction in combination studies. (2010) (5)
Phase II clinical trial of ixabepilone in metastatic breast cancer (MBC) patients previously untreated with taxanes. (2006) (5)
Calcium carbonate treatment of diarrhoea in intestinal bypass patients (1996) (5)
Female Gender Predicts Augmented Immune Infiltration in Lung Adenocarcinoma. (2020) (5)
Optimal continuous-monitoring design of single-arm phase II trial based on the simulated annealing method. (2013) (5)
Comparing three regularization methods to avoid extreme allocation probability in response-adaptive randomization (2018) (5)
The value of interventional radiology in clinical trial teams: experience from the BATTLE lung cancer trials. (2020) (5)
DNA damage in peripheral blood mononuclear cells correlates with response to biochemotherapy in melanoma (1998) (5)
T cell repertoire analysis of non-small cell lung cancer patients treated with neoadjuvant nivolumab alone or in combination with ipilimumab (NEOSTAR trial). (2019) (5)
Risk Factors for and Time to Recurrence of Symptomatic Malignant Pleural Effusion in Patients with Metastatic Non-Small Cell Lung Cancer with EGFR or ALK Mutations. (2020) (5)
PI3‐kinase pathway biomarkers in oral cancer and tumor immune cells (2018) (5)
Prediction-Oriented Marker Selection (PROMISE): With Application to High-Dimensional Regression (2017) (5)
Pembrolizumab in Patients with Refractory Cutaneous Squamous Cell Carcinoma: A Phase II Trial (2021) (5)
Surgical Outcomes in Cancer Patients Undergoing Elective Surgery After Recovering from Mild-to-Moderate SARS-CoV-2 Infection (2021) (5)
Frequent expression of MAGE1 tumor antigens in bronchial epithelium of smokers without lung cancer. (2011) (5)
First-in-human safety, pharmacokinetics, and preliminary efficacy of TPX-0022, a novel inhibitor of MET/SRC/CSF1R in patients with advanced solid tumors harboring genetic alterations in MET (2020) (4)
Network for Biomarker Immunoprofiling for Cancer Immunotherapy: Cancer Immune Monitoring and Analysis Centers and Cancer Immunologic Data Commons (CIMAC-CIDC) (2021) (4)
Intrathecal (IT) and intravenous (IV) nivolumab (N) for metastatic melanoma (MM) patients (pts) with leptomeningeal disease (LMD). (2021) (4)
Phase I clinical trial: pharmacokinetics of a novel anthracycline, DA-125 and metabolites. Single dose study. (1998) (4)
Evaluating Bayesian adaptive randomization procedures with adaptive clip methods for multi-arm trials (2021) (4)
Borrowing strength and borrowing index for Bayesian hierarchical models (2020) (4)
Immunogenomic profiling of lung adenocarcinoma reveals poorly differentiated tumors are associated with an immunogenic tumor microenvironment. (2022) (4)
Phase I study of weekly alternating therapy with irinotecan/cisplatin and etoposide/cisplatin for patients with small-cell lung cancer. (2003) (4)
A phase III study of Æ-941 with induction chemotherapy (IC) and concomitant chemoradiotherapy (CRT) for stage III non- small cell lung cancer (NSCLC) (NCI T99–0046, RTOG 02–70, MDA 99–303) (2007) (4)
A randomized double-blind study of the biological effects of celecoxib as a chemopreventive agent in current and former smokers (2008) (4)
Pathologic assessment following neoadjuvant immunotherapy or chemotherapy demonstrates similar patterns in non-small cell lung cancer (NSCLC). (2018) (4)
Susceptibility and Prevention Δ Np 63 Overexpression , Alone and in Combination with Other Biomarkers , Predicts the Development of Oral Cancer in Patients with Leukoplakia (2009) (4)
Response to single-agent (SA) chemotherapy (CTx) after immunotherapy exposure in non-small cell lung cancer (NSCLC). (2017) (4)
Prognostic biomarkers in patients with human immunodeficiency virus‐positive disease with head and neck squamous cell carcinoma (2017) (4)
p 53 Protein Accumulation and Genomic Instability in Head and Neck Multistep Tumorigenesis 1 (2001) (4)
Phase III randomized trial of primary chemotherapy with doxorubicin/cyclophosphamide (AC) vs docetaxel/capecitabine (TX) for stage II/III breast cancer (BC): Interim analysis. (2004) (4)
BATLLE-2: KRAS mutation and outcome in a biomarker-integrated study in previously treated patients (pts) with advanced non-small cell lung cancer (NSCLC). (2014) (4)
Distinct immune gene programs associated with host tumor immunity, neoadjuvant chemotherapy and chemoimmunotherapy in resectable NSCLC. (2022) (4)
Histology determination of lung cancers: A report on genomic profiling of lung cancer of mixing histology. (2017) (4)
Surgical Outcomes Following Nivolumab or Nivolumab Plus Ipilimumab In Non-Small Cell Lung Cancer (2022) (4)
Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study (2019) (4)
Novel Bayesian Adaptive Designs and Their Applications in Cancer Clinical Trials (2020) (3)
Treatment patterns and outcomes of palliative systemic therapy in patients with salivary duct carcinoma and adenocarcinoma, not otherwise specified (2021) (3)
Abstract PL01-03: The landscape of cancer prevention: Personalized approach in lung cancer (2011) (3)
Rational Clinical Experiment: Assessing Prior Probability and Its Impact on the Success of Phase II Clinical Trials. (2015) (3)
Monotonic single‐index models to assess drug interactions (2017) (3)
Profiling of cytokines and angiogenic factors (C/AF) in head and neck (HN) cancer correlates circulating biomarkers with clinical outcomes following induction chemotherapy (2008) (3)
Cotargeting Cyclin D 1 Starts a New Chapter in Lung Cancer Prevention and Therapy (2011) (3)
Author Correction: Circulating tumor DNA analysis depicts subclonal architecture and genomic evolution of small cell lung cancer (2019) (3)
Screening for PIK3CA mutations, PTEN loss, and RAS/RAF mutations in early-phase protocols with PI3K/mTOR pathway inhibitors. (2011) (3)
Adaptive clinical trial designs in oncology. (2014) (3)
OC-0143: A Bayesian randomisation trial of IMRT vs. PSPT for locally advanced non-small cell lung carcinoma (2016) (3)
809 Phase 2 trial of neoadjuvant and adjuvant PD-1 checkpoint blockade in local-regionally advanced, resectable HNSCC indicates pathological response is associated with high disease-free survival (2020) (3)
Novel Statistical Models for NSCLC Clinical Trials (2014) (3)
Applying Emax model and bivariate thin plate splines to assess drug interactions. (2010) (3)
Abstract 5391: Systemic gene therapy with tumor suppressor TUSC2/FUS1 nanoparticles for recurrent/metastatic lung cancer (2011) (3)
Phase I Trial of Weekly Topotecan and Gemcitabine in Patients With Solid Tumors (2009) (3)
Impact of genomic aberrations and additional therapies on survival outcomes of patients with operable non-small cell lung cancer (NSCLC) from the NEOSTAR study. (2021) (3)
Melding a New 3-Dimensional Agarose Colony Assay with the Emax Model to Determine the Effects of Drug Combinations on Cancer Cells (2009) (3)
Cross-Site Concordance Evaluation of Tumor DNA and RNA Sequencing Platforms for the CIMAC-CIDC Network (2020) (3)
Response adaptive randomization procedures in seamless phase II/III clinical trials (2020) (3)
A Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma (2020) (3)
The use of local and nonlocal priors in Bayesian test‐based monitoring for single‐arm phase II clinical trials (2021) (3)
Validation of a Novel Statistical Model for Assessing the Synergy of Combined-Agent Cancer Chemoprevention (2010) (3)
Immune Profiling Mass Cytometry Assay Harmonization: Multicenter Experience from CIMAC-CIDC (2021) (3)
Clinical Trial Design for Anticancer Therapies (2007) (3)
Single-arm study of bimiralisib in head and neck squamous cell carcinoma (HNSCC) patients (pts) harboring NOTCH1 loss of function (LOF) mutations. (2020) (3)
Therapeutic Target for Overcoming EGFR Inhibitor Resistance Resistance to EGFR and PI 3 K Inhibitors and Identifies Axl as a Mesenchymal Transition Gene Signature Predicts (2012) (2)
Impact of COVID-19 pandemic on oncology clinical trial design, data collection and analysis (2022) (2)
Reply to A. Levy et al. (2013) (2)
Antitumor activity of AZ 64 via G 2 / M arrest in non-small cell lung cancer (2)
Induction chemotherapy with or without erlotinib in patients with head and neck squamous cell carcinoma amenable for surgical resection. (2022) (2)
Abstract B161: PIK3CA mutations H1047R are associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials. (2011) (2)
personalized medicine Bayesian adaptive design for targeted therapy development in lung cancera step toward (2010) (2)
Evaluation of bias for outcome adaptive randomization designs with binary endpoints (2020) (2)
Human Cancer Biology ETS 2 Mediated Tumor Suppressive Function and MET Oncogene Inhibition in Human Non – Small Cell Lung Cancer (2013) (2)
Surgical outcomes after nivolumab or nivolumab with ipilimumab treatment in patients with non-small cell lung cancer. (2022) (2)
Survival prolongation by rationale innovative genomics (SPRING): An international WIN consortium phase I study exploring safety and efficacy of avelumab, palbociclib, and axitinib in advanced non-small cell lung cancer (NSCLC) with integrated genomic and transcriptomic correlates (2019) (2)
Imaging , Diagnosis , Prognosis EZH 2 Protein Expression Associates with the Early Pathogenesis , Tumor Progression , and Prognosis of Non – Small Cell Lung Carcinoma (2013) (2)
Randomized phase II cross-over sequential chemotherapy trial of irinotecan/cisplatin (IP) vs. gemcitabine/vinorelbine (GV) in chemo-naïve patients with stage IIIb/IV non-small cell lung cancer (NSCLC). (2006) (2)
A phase I/II study combining dasatinib (D) and erlotinib (E) in non-small cell lung cancer. (2013) (2)
A WIN Consortium phase I study exploring avelumab, palbociclib, and axitinib in advanced non‐small cell lung cancer (2022) (2)
Phase I study of pemetrexed in recurrent/metastatic head and neck squamous cell cancer (HNSCC) and to assess the need for steroid premedication. (2009) (2)
Erratum: Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with β-blockers (Science Translational Medicine DOI: 10.1126/scitranslmed.aao4307) (2019) (2)
RESULTS OF A PHASE II/III TRIAL OF CELECOXIB TO PREVENT RECURRENCE OF NON-MUSCLE INVASIVE BLADDER CANCER (2009) (2)
Inhibition of the Phosphatidylinositol-3 Kinase Pathway Using Bimiralisib in Loss-of-Function NOTCH1-Mutant Head and Neck Cancer (2022) (2)
A Comparative Study of Bayesian Optimal Interval (BOIN) Design With Interval 3 + 3 (i3 + 3) Design for Phase I Oncology Dose-Finding Trials (2020) (2)
Accumulation of p53 Protein and Retinoic Acid Receptorin Retinoid (1997) (2)
TCR Repertoire of Lung Cancer: An Association with Tumor Molecular and Clinicopathological Features (2017) (2)
Calibrating the prior distribution for a normal model with conjugate prior (2015) (2)
9-cis-retinoic acid treatment increases serum concentrations of alpha-tocopherol in former smokers. (2005) (2)
Abstract 787: Differences in protein expression patterns in lung adenocarcinomas arising in never versus ever smokers (2010) (2)
Phase I study of mesenchymal stem cell (MSC)-derived exosomes with KRASG12D siRNA in patients with metastatic pancreatic cancer harboring a KRASG12D mutation. (2022) (2)
Predictive value of phase II clinical trials in pancreatic cancer: Rethinking the road to progress. (2013) (2)
Erratum: High expression of folate receptor alpha in lung cancer correlates with adenocarcinoma histology and mutation (Journal of Thoracic Oncology (2012) 7 (520-527)) (2012) (2)
DNA methyltransferase-3B (DNMT3B) in oral cancer (OC) development. (2011) (2)
Association of the T-cell receptor landscape with survival in non-small cell lung cancer. (2018) (2)
Abstract 4256: High programmed cell death ligand 1 expression and low immune infiltrate score correlate with worse outcome in patients with lung adenocarcinoma (2015) (2)
Biologic risk model for recurrence in resected early-stage non-small cell lung cancer (ES NSCLC). (2011) (2)
during NSAID-induced Apoptosis in Colorectal Cancer Cells GATA-6 Transcriptional Regulation of 15-Lipoxygenase-1 Updated (2002) (2)
A Phase I trial of intravenous melphalan, paclitaxel, and cisplatin plus granulocyte‐colony stimulating factor in patients with suboptimal advanced epithelial ovarian carcinoma or peritoneal carcinoma (1999) (2)
An analysis of research biopsy core variability from over 5000 prospectively collected core samples (2021) (2)
A phase I study of sunitinib in combination with sirolimus in adults with advanced refractory malignancies. (2009) (2)
Randomized phase II trial of weekly paclitaxel, carboplatin, cetuximab (PCC) versus cetuximab, docetaxel, cisplatin, and fluorouracil (C-TPF) in previously untreated patients with locally advanced head and neck squamous cell carcinoma. (2014) (2)
Distinct pattern of TP 53 mutations in human immunodeficiency virus-related head and neck squamous cell carcinoma (2)
SPRING: A Worldwide Innovative Network (WIN) Consortium phase I study of triple therapy (avelumab, axitinib, and palbociclib) in advanced non-small cell lung cancer (NSCLC) with genomic and transcriptomic correlates. (2020) (2)
Impact of Region-of-Interest Size on Immune Profiling Using Multiplex Immunofluorescence Tyramide Signal Amplification for Paraffin-Embedded Tumor Tissues (2022) (2)
Clinical Effectiveness and Safety of Anti-PD-(L)1 Therapy Among Older Adults With Advanced Non-Small Cell Lung Cancer. (2022) (1)
Clinical Characteristics and Cause of Death Among Hospitalized Decedents With Cancer and COVID-19 (2022) (1)
PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Bene ﬁ t from Immune Checkpoint Blockade than HLA Class I Genotype in Non – Small Cell Lung Cancer (1)
Abstract 4054: Gene expression difference (GED) revealed immune function gene down-regulation as tumor-associated inflammatory cell (TAIC) infiltration in microenvironment in non-small cell lung cancer (NSCLC) (2018) (1)
Local consolidation therapy (LCT) after first line tyrosine kinase inhibitor (TKI) for patients with EGFR mutant metastatic non-small cell lung cancer (NSCLC). (2017) (1)
Do elderly chemorefractory NSCLC patients derive benefit from salvage targeted therapy? Subgroup analysis of clinical outcome and toxicity from the BATTLE trial. (2011) (1)
Predictive Biomarkers and Personalized Medicine Genetic Variants in the PI 3 K / PTEN / AKT / mTOR Pathway Predict Head and Neck Cancer Patient Second Primary Tumor / Recurrence Risk and Response to Retinoid Chemoprevention (2012) (1)
Abstract 4819: Gene-expression profiles predict sorafenib efficacy in wild-type EGFR non-small cell lung cancer (NSCLC) (2012) (1)
Differences in mutation patterns of diagnostic versus post-chemotherapy samples in patients with metastatic non-small cell lung cancer (NSCLC). (2013) (1)
Abstract 2877: Focal adhesion kinsase (FAK) protein overexpression and gene copy number gain correlate with better outcome in patients with surgically resected NSCLC tumors (2014) (1)
Relationship between level of lymph node metastasis (LNM) and survival in head and neck squamous cell carcinoma (HNSCC). (2013) (1)
Abstract 142: Mutation and immune profiles in early-stage lung squamous cell carcinoma (2016) (1)
Error in a Supplement. (2021) (1)
Systematic review of a personalized strategy in cancer clinical trials leading to FDA approval. (2014) (1)
New DNA methylation markers associated with oral cancer (OC) development (dvlpt). (2012) (1)
S phase determination in intact colonic crypts by histone H3 messenger RNA in situ hybridization and confocal microscopy. (1997) (1)
Phase I trial of neoadjuvant dasatinib in patients with resectable malignant pleural mesothelioma. (2009) (1)
Principles and Reporting of Bayesian Trials. (2020) (1)
Expression of phospho(p)-AMP-activated protein kinase (AMPK) in lung cancer (2008) (1)
Multiregion whole exome seuquencing of pre- and early neoplastic lung lesions. (2017) (1)
Limited Benefit from the Addition of Immunotherapy to Chemotherapy in TKI-Refractory EGFR-Mutant Lung Adenocarcinoma (2022) (1)
Interplay between immune infiltration and tumor progression and survival in non-small cell lung cancer: An analysis of institutional and public data. (2017) (1)
Alternative dosing of exemestane in postmenopausal women with ER-positive breast cancer. Design and methods of a randomized presurgical trial (2021) (1)
platform design using predictive probability (2016) (1)
Prospective evaluation of a 409-gene next generation sequencing platform to facilitate genotype-matched clinical trial enrollment. (2015) (1)
Abstract PR-03: Genetic variations in microRNA biogenesis genes as predictors for risk of second primary tumor (SPT) and/or recurrence in patients with early‐stage head and neck cancer (2010) (1)
A clinical trial design applying Bayesian adaptive randomization for targeted therapy development in lung cancer: A step toward personalized medicine (2007) (1)
Software for Design and Analysis of Clinical Trials (2012) (1)
Outcomes of patients with oropharyngeal squamous cell carcinoma treated with induction chemotherapy followed by concurrent chemoradiation compared with those treated with concurrent chemoradiation (2021) (1)
P3-093: Correlative analyses of plasma cytokine / angiogenic factor (C/AF) profile, gender and outcome in a randomized, three-arm, phase II trial of 1st-line vandetanib (VAN) and / or carboplatin plus paclitaxel (CP) for advanced non small cell lung cancer (NSCLC). (2007) (1)
Abstract 1174: Characterization of the immunologic intra-tumor heterogeneity in early stages of non-small cell lung carcinoma using multiplex immunofluorescence and image analysis approaches (2018) (1)
Phase II pilot study of neoadjuvant docetaxel and cisplatin followed by adjuvant erlotinib in patients with stage I-III non-small cell lung cancer (NSCLC). (2009) (1)
Vimentin (EMT Marker Protein) Score Predicts Resistance to Erlotinib and Radiation Therapy for Patients With Stage III Non-small Cell Lung Cancer on a Prospective Phase II Trial (2012) (1)
Efficacy of Alternative Dose Regimens of Exemestane in Postmenopausal Women With Stage 0 to II Estrogen Receptor-Positive Breast Cancer: A Randomized Clinical Trial. (2023) (1)
Intratumor Heterogeneity Is Associated with Survival of Patients with Stage IA Lung Adenocarcinoma (2017) (1)
Abstract 2658: Phase II study of chemoradiation therapy and erlotinib for stage III non-small cell lung cancer (2011) (1)
The Reality of Randomized Controlled Trials for Assessing the Benefit of Proton Therapy: Critically Examining the Intent-to-Treat Principle in the Presence of Insurance Denial (2020) (1)
Clinical outcome and potential benefits of post-progression immunotherapy for patients with metastatic NSCLC with primary resistance to ipilumumab and nivolumab in the LONESTAR phase III study. (2022) (1)
Abstract OT2-09-01: Pilot study of denosumab inBRCA1/2mutation carriers scheduling for risk-reducing salpingo-oophorectomy (2019) (1)
Abstract A21: Tissue platinum concentration and tumor response in non-small cell lung cancer (2012) (1)
Abstract 955: Specific forms of mutant KRAS predict patient benefit from targeted therapy in the BATTLE-1 clinical trial in advanced non-small cell lung cancer (2011) (1)
Allergic Mediator Histamine Confers Immunotherapy Resistance in Cancer Patients via Histamine Receptor 1 on Macrophage (2020) (1)
Habitat Imaging Biomarkers for Diagnosis and Prognosis in Cancer Patients Infected with COVID-19 (2022) (1)
RE: Meta-analysis of the relationship between dose and benefit in phase I targeted agent trials. (2013) (1)
OA20.05 The Influence of Neoadjuvant Chemotherapy, on Immune Response Profile in Non-Small Cell Lung Carcinomas (2017) (1)
Statistical Methods in Precision Oncology. (2020) (1)
TCF-001 TRACK (Target Rare Cancer Knowledge): A national patient-centric precision oncology trial for rare cancers. (2021) (1)
Intratumor heterogeneity of stage IA lung adenocarcinoma by multiregion whole exome sequencing and association with survival. (2017) (1)
Fibroblast growth factor receptor 1 (FGFR1) gene copy number gain in adenocarcinoma and squamous cell carcinoma of the lung. (2013) (1)
Phase II study of induction chemotherapy (ICT) with gemcitabine (G) and vinorelbine (V) followed by concurrent chemoradiation therapy (CCRT) with oral etoposide (E) and cisplatin (P) for inoperable stage IIIA/B non-small cell lung cancer (NSCLC) (2004) (1)
Abstract OT1-04-03: Alternative dosing of exemestane before surgery in postmenopausal patients with stage 0-II estrogen receptor positive breast cancer: Design and methodology (2020) (1)
Molecular characterization of the PI3/Akt pathway in head and neck squamous cell cancer (HNSCC). (2004) (1)
CIMAC-CIDC tissue imaging harmonization. (2020) (1)
Abstract 5377: Tracking genomic and epigenomic evolution from preneoplastic lesions to lung adenocarcinoma by multiregion sequencing (2018) (1)
Retinoic A cid R eceptor-Beta a s a P rognostic I ndicator i n Stage I N on-Small-Cell L ung C ancer (2000) (0)
Inferential Frameworks for Clinical Trials (2020) (0)
CCR Perspectives in Drug Approval (2013) (0)
Prediction-Oriented Marker Selection (PROMISE): With Application to High-Dimensional Regression (2017) (0)
Abstract A76: Prospective evaluation of two-phase NGS platform coupled to active precision oncology decision support in the therapeutic management of patients with advanced cancers (2015) (0)
Combination of Radiation Therapy and Intratumoral IL-12/GM-CSF Leads to Systemic Toxicity in Pet Dog Subjects with Refractory Solid Tumors (2018) (0)
(S016) Erlotinib May Enhance Radiation Effects in Patients With Stage III Non-small-cell Lung cancer (2017) (0)
Prospective Imaging Biomarker Assessment of Mortality Risk in Patients Treated with Head and Neck Radiotherapy (2011) (0)
Targeting the insulin-like growth factor receptor and Src signaling network for the treatment of non-small cell lung cancer (2015) (0)
Investigation of profile-related evidence determining individualized cancer therapy (I-PREDICT) in heavily pre-treated patients: A role for combinatorial precision cancer therapy. (2018) (0)
Final Results of a Prospective Phase 2 Study of Adding Erlotinib to Chemoradiation for patients With Stage III Non–small Cell Lung Cancer (2017) (0)
Oral Neoplasia Multimodal Optical Imaging for Detection of In Vivo Accuracy of Updated (2012) (0)
Evolution of the DNA methylome from precancer to invasive lung adenocarcinoma (2020) (0)
Dose-response relationships in phase I trials: Are patients treated at lower doses at a disadvantage? (2009) (0)
Comparative assessment of the eighth and seventh AJCC staging edition prognostic performance of patients with p16 positive oropharynx cancer. (2021) (0)
Diffusion Capacity of the Lungs Following Passive-Scattering Proton Therapy and Intensity-Modulated Photon Radiation Therapy for Locally Advanced Non–small Cell Lung Cancer (2017) (0)
P h a s e I I a n d B i o logic S tudy o f I nterferon A lfa, R etinoic Acid, a nd C isplatin i n A dvanced S quamous S kin C ancer (2002) (0)
ASO Visual Abstract: Surgical Outcomes for Cancer Patients Undergoing Elective Surgery after Recovering from Mild to Moderate SARS-CoV-2 Infection (2021) (0)
Local therapy of primary disease and survival in non-small cell lung cancer metastatic to brain and other single organ sites (2008) (0)
Abstract 5578: SOCS2 (suppressor of cytokine signaling protein 2) is a prognostic indicator of progression-free survival in head and neck squamous cell carcinoma (HNSCC) patients. (2013) (0)
Spatial PD‐L1, immune‐cell microenvironment, and genomic copy‐number alteration patterns and drivers of invasive‐disease transition in prospective oral precancer cohort (2023) (0)
Adaptive Designs for Effi cacy and Toxicity Endpoints in Early Drug Development (2008) (0)
Genetic variants in the telomere maintenance pathway as predictors of second primary tumors and recurrence of early-stage head and neck cancer. (2010) (0)
Expression of fibroblast growth factor and its receptors in premalignant and malignant human lung tissues. (2006) (0)
Predictive Biomarkers and Personalized Medicine DNA Repair Biomarker Profiling of Head and Neck Cancer : Ku 80 Expression Predicts Locoregional Failure and Death following Radiotherapy (2011) (0)
Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC. (2023) (0)
Abstract 745: Oncostatin M receptor activation leads to molecular targeted therapy resistance in non-small cell lung cancer (2015) (0)
Checkpoint inhibitors assessment in oropharynx carcinoma (CIAO). (2018) (0)
Multi-Center Immune Profiling Mass Cytometry Assay Harmonization. (2021) (0)
Abstract 89: Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma (2016) (0)
A Randomized Clinical Trial on Anterior Approach vs Conventional Hepatectomy for Resection of Colorectal Liver Metastasis-To Terminate or Not to Terminate the Study. (2021) (0)
Adaptive Designs for Efficacy and Toxicity Endpoints in Early Drug Development (2008) (0)
Multiomics profiling and association with molecular and immune features in association with benefits from immunotherapy for patients with previously treated stage IV or recurrent squamous cell lung cancer from the phase III SWOG LungMAP S1400I trial. (2022) (0)
Abstract 3431: Molecular determinants of KRAS p.G12C inhibitor efficacy in advanced NSCLC (2023) (0)
Implementation of a novel patient-reported outcomes measure for patients with cancer and COVID-19 infection. (2021) (0)
Abstract LB-186: MET receptor tyrosine kinase is a potential novel target for prevention of oral cancer. (2013) (0)
Microenvironment and Immunology CXCR 2 Expression inTumorCells Is aPoorPrognosticFactor and Promotes Invasion and Metastasis in Lung Adenocarcinoma (2013) (0)
Protective effects of in vivo 13-cis-retinoic acid treatment against mutagen-induced genetic damage (1994) (0)
P124 Alpha-type 1 polarized dendritic cells loaded with apoptotic allogeneic breast cancer cells can induce potent cytotoxic T lymphocytes against breast cancer (2011) (0)
Abstract 3576: Rictor alterations elicit non-canonical signaling mechanisms contributing to tumorigenicity and therapeutic resistance in non-small cell lung cancer (NSCLC) (2015) (0)
Abstract 392: CXCR2 expression in tumor cells is associated with an adverse outcome in a large set of non-small-cell lung cancer (NSCLC) (2011) (0)
Benchmarking Outcomes for Molecularly Characterized Synchronous Oligometastatic Non–Small-Cell Lung Cancer Reveals EGFR Mutations to Be Associated With Longer Overall Survival (2023) (0)
The demographic and clinical characteristics of subcortical vascular dementia: An analysis of 125 patients (2009) (0)
Concordance of oral HPV prevalence between patients with oropharyngeal cancer and their partners (2016) (0)
A luminescence-based assay for evaluating bactericidal antibody to Borrelia burgdorferi in vaccinated horses' serum. (2019) (0)
Abstract 1974: Immune gene expression signatures associated clinical benefit from nivolumab and ipilimumab for previously treated patients with stage IV squamous cell lung cancer: An immune biomarker analysis of phase III SWOG LungMAP S1400I trial (2022) (0)
Real-world effectiveness of immune checkpoint inhibitors alone or in combination with chemotherapy in metastatic non–small cell lung cancer. (2022) (0)
Biology of Human Tumors VEGF / VEGFR-2 Upregulates EZH 2 Expression in Lung Adenocarcinoma Cells and EZH 2 Depletion Enhances the Response to Platinum-Based and VEGFR-2 – Targeted Therapy (2014) (0)
Abstract 4264: The genomic landscape of RET fusions in non-small cell lung cancer and the impact of co-occurring genomic alterations on the efficacy of selective RET inhibitors (2023) (0)
Abstract B17: Phase I prevention study of atorvastatin in women at increased risk for breast cancer (2012) (0)
Abstract 3162: Prognostic value of tumor mutational burden using a 409 gene NGS panel in cancer patients with advanced stage recurrent or treatment refractory disease (2019) (0)
Abstract 399: Tertiary lymphoid structures features associate with outcome in non-small cell lung carcinoma (2020) (0)
Robust and Efficient Assessment of Potency (REAP) as a quantitative tool for dose-response curve estimation (2021) (0)
Abstract 1901: EGFR and K-Ras mutations and resistance of lung cancers to IGF-1R TKI (2012) (0)
Abstract A12: High-throughput mutation analysis of NSCLC circulating tumor cells (2012) (0)
Abstract LB-195: A double-blind randomized controlled multisite trial evaluating tissue effects of preoperative finasteride in clinically organ-confined prostate cancer: Pathologic outcomes. (2013) (0)
P2.01-061 Image Analysis-Based Expression of Nine Immune Checkpoints Identifies Distinct Immunoprofiling Patterns in Non-Small Cell Lung Carcinomas: Topic: Immune Mechanisms in Thoracic Cancer and Targeted Therapy (2017) (0)
Abstract 1255: Loss of the ubiquitin protease USP18 represses KRAS mutant lung cancer tumorigenicity in mice by destabilizing KRAS protein (2016) (0)
Clinical Targeting of VEGF and EGFR Effective in Non-Small Cell Lung Cancer (2004) (0)
Immune cellular patterns of distribution affect outcomes of patients with non-small cell lung cancer (2023) (0)
Abstract IA06: Adaptive designs and adaptive learning for biomarker-based clinical trials for targeted therapies. (2014) (0)
Implication of insulin-like growth factor (IGF)/IGF binding protein-3 and alpha-tocopherol in the chemopreventive activity of 9-cis retinoic acid in lung cancer. (2004) (0)
962 Integrative immunomics highlight the immunomodulatory impact of neoadjuvant chemotherapy and immune-based treatments in resected non-small-cell lung cancer (2021) (0)
HSR19-085: A Real World Observational Assessment of the Impact of Immunotherapy on the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) (2019) (0)
Abstract 4648: High membrane carbonic anhydrase IX (CAIX) expression predicts relapse of resected stage I-II non-small cell lung cancer (NSCLC) (2010) (0)
Abstract 1981: MYC downregulation and chemoresistance in non-small cell lung cancer (NSCLC): Evidence from the Biomarker-Based Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) program (2010) (0)
Abstract 6152: Distinct immune gene programs associated with host tumor immunity, neoadjuvant chemotherapy and chemoimmunotherapy in resectable NSCLC (2022) (0)
Assessment of Drug Interactions with Repeated Measurements (2017) (0)
Abstract 4662: Beta blockers abrogate EGFR TKI resistance induced by adrenergic receptor-mediated upregulation of IL-6 and modulation of the LKB1/AMPK/mTOR axis (2016) (0)
Abstract 2580: Infiltration and spatial distribution of immune cells are associated clinical benefit from Nivolumab and Ipilimumab for previously treated patients with stage IV squamous cell lung cancer: an immune biomarker analysis of Phase III SWOG LungMAP S1400I trial (2022) (0)
Incorporating historical information and real-world evidence to improve phase I clinical trials (2020) (0)
Prognostic factors in early stage head and neck squamous cell carcinoma (HNSCC) patients in a prospective clinical trial. (2004) (0)
WS-04-04: Novel clinical trial design applying Bayesian adaptive randomization for targeted therapy in lung cancer – A step toward personalized medicine (2007) (0)
Abstract 3633: Immunofluorescence profiling of co-expression of multiple immune checkpoints in malignant and tumor infiltrated lymphocytes in non-small cell lung carcinomas using image analysis system (2018) (0)
Circulating tumor DNA analysis depicts subclonal architecture and genomic evolution of small cell lung cancer (2018) (0)
Plasma cytokine concentrations and quality of life in patients with non-small cell lung cancer in a phase II trial of first-line treatment with carboplatin-paclitaxel and/or vandetanib. (2009) (0)
Abstract 4121: Folate pathway in malignant pleural mesothelioma (MPM): Novel therapeutic opportunities due to folate receptor alpha overexpression (2011) (0)
A phase I study of neoadjuvant cisplatin (C), docetaxel (D) and nintedanib (N) for resectable non-small cell lung cancer (NSCLC). (2018) (0)
Abstract 2934: Neoadjuvant chemotherapy influence changes of the immune response in non-small cell lung carcinomas immune response in non-small cell lung carcinomas (2017) (0)
Abstract ED01-01: Report card for chemoprevention trials: The good, the bad and the ugly-How can we do better? (2012) (0)
Podoplanin is overexpressed in head and neck squamous cell carcinomas (HNSCC) and is associated with poor clinical outcome (2006) (0)
Importance of tumor location and histology in long term survivors (LTS) of non small cell lung cancer (NSCLC) treated without surgery (2008) (0)
New perspectives on metastatic patterns in lung cancer: The M. D. Anderson thoracic medical oncology database (2007) (0)
Abstract 2790: Characterization of the immune microenvironment in brain metastasis from non-small cell lung cancer (2019) (0)
Frequent expression of MAGE tumor antigens in bronchial epithelium of chronic smokers without lung cancer (2007) (0)
280 Clinical outcomes of immunotherapy continued beyond radiographic progression in older adults with advanced non-small cell lung cancer (2021) (0)
Early phase trials bridging the gap between prevention and treatment. (2006) (0)
Abstract 3195: Formalin-fixed and paraffin-embedded (FFPE) DNA recovery for high-throughput genotyping of lung cancer tissues (2012) (0)
Angiogenesis in non-small cell lung cancer (NSCLC): Gender differences in tumor and circulating angiogenic factors (2007) (0)
Comprehensive T cell repertoire characterization of non-small cell lung cancer (2020) (0)
A randomized presurgical trial of alternative dosing of exemestane in postmenopausal women with early-stage ER-positive breast cancer. (2022) (0)
Abstract A212: Next generation sequencing (NGS) in 57 patients with advanced or metastatic breast cancer: Identification of unique genomic profiles and correlation with response. (2013) (0)
Abstract OT3-15-02: A randomized, double-blind, placebo-controlled study of 4-hydroxytamoxifen topical gel in women with mammographically dense breasts (2020) (0)
Abstract 374:VEGFR2/KDRpolymorphisms and gene copy gain with outcome in non-small cell lung cancer (2010) (0)
Abstract PS8-12: Interim analysis of a phase I dose escalation study of topical bexarotene in women at high risk for breast cancer (2021) (0)
Association between human papillomavirus (HPV) status with serum cytokine and angiogenic factor (CAF) profile after induction chemotherapy in head and neck squamous cell carcinoma (HNSCC). (2009) (0)
Treatment patterns and systemic therapy outcomes for patients with salivary duct carcinoma and adenocarcinoma NOS. (2021) (0)
Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma in Situ (2023) (0)
Abstract 1180: Impact of the spatial analysis of tumor-associated lymphocytes and tumor-associated macrophages on recurrence at early stage of non-small cell lung carcinoma (2019) (0)
Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naïve study (2021) (0)
Cyclin D1 polymorphism, biochemoprevention and risk of upper aero-digestive tract cancer development. (2004) (0)
Genomic evolutions in the progression from lung preneoplasia to adenocarcinoma. (2018) (0)
Genomic and TCR Repertoire Intratumor Heterogeneity of Small-cell Lung Cancer and its Impact on Survival (2020) (0)
Abstract #LB-265: Identification of prognostic markers by integrative gene expression analysis of an in vitro model of lung carcinogenesis and their validation in lung cancer tissue specimens (2009) (0)
Incidence and risk factors for pneumonitis associated with immune checkpoint inhibitors in advanced-stage non-small cell lung cancer: A single center experience. (2020) (0)
Author Correction: Multi-region exome sequencing reveals genomic evolution from preneoplasia to lung adenocarcinoma (2021) (0)
Clinical Implications of Geometric and Dosimetric Uncertainties Due to Inter- and Intra-Fractional Movement During Volumetric Modulated Arc Therapy for Breast Cancer Patients. (2021) (0)
Bayesian Two-Stage Biomarker-Based Adaptive Design for Targeted Therapy Development (2014) (0)
Advances in Brief Adenovirus-mediated Wild-Type p 53 Gene Transfer Down-Regulates Vascular Endothelial Growth Factor Expression and Inhibits Angiogenesis in Human Colon Cancer 1 (2006) (0)
Phase I Dose Escalation Study of Topical Bexarotene in Women at High Risk for Breast Cancer. (2022) (0)
Abstract B94: Pharmacogenetics of retinoid chemoprevention in head and neck cancer patients: Modulation of response by common genetic variation in the mTOR signaling pathway (2010) (0)
Evolution of DNA methylome from precancerous lesions to invasive lung adenocarcinomas (2021) (0)
Abstract 4109: A 5-gene signature (sig) predicts clinical benefit from erlotinib in non-small cell lung cancer (NSCLC) patients (pts) harboring wild-type (wt) EGFR & KRAS (2011) (0)
Expression of D DNMT 3 B Variants and Its Association with Promoter Methylation of p 16 and RASSF 1 A in Primary Non – Small Cell Lung Cancer (2006) (0)
Auto-reactive antibodies as predictive markers for immune checkpoint–induced pneumonitis. (2022) (0)
49 PHASE II STUDY ERLOTINIB/RT AND CHT/RT FOLLOWED BY CONSOLIDATION OF CHT FOR PATIENTS WITH STAGE III NON-SMALL CELL LUNG CANCER (NSCLC): ANALYSIS OF PATIENT SPECIMENS FOR BIOMARKERS (2012) (0)
P1.04-07 Immune Suppressive Microenvironment and Highly Clonal Concordance of TCR Repertoire in Brain Metastases from Non-Small Cell Lung Cancer (2019) (0)
1 JAK 1 / STAT 3 activation through a proinflammatory cytokine pathway leads to resistance to molecularly targeted therapy in non-small cell lung cancer (2017) (0)
Abstract 1122: Insulin receptor expression and survival of patients with non-small cell lung cancer (2011) (0)
Author Correction: Circulating tumor DNA analysis depicts subclonal architecture and genomic evolution of small cell lung cancer (2019) (0)
Abstract 3685: Analysis of EZH2 and TTF-1 protein expression identifies a subset of lung adenocarcinomas with better prognosis (2012) (0)
Phase III trial of adjuvant 13- cis -retinoic acid and interferon-alpha for patients with aggressive skin squamous cell carcinoma. (2006) (0)
P125 Application of biomarkers to sentinel lymph node biopsy for the management of breast cancer (2011) (0)
Personalized therapy in diverse cancers: Meta-analysis of 32,149 patients in phase II clinical trials. (2015) (0)
Abstract 1716: Targeting the insulin-like growth factor receptor/Insulin receptor and Src signaling network for the treatment of non-small cell lung cancer (2014) (0)
OA15.04 Genomic and TCR Intratumor Heterogeneity of Small-Cell Lung Cancer by Multiregion Sequencing: An Association with Survival (2019) (0)
Correction to: CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinoma (2021) (0)
Abstract CN07-05: Efficient designs for lung cancer prevention trials: Lessons learned and moving forward (2010) (0)
Expression of tumor biomarkers in HIV-infected patients with head and neck cancer. (2014) (0)
Second primary tumors (SPTs) in patients (PTS) with non-small cell lung cancer (NSCLC): A retrospective cohort study (2005) (0)
Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial (2019) (0)
Author Correction: Multi-region exome sequencing reveals genomic evolution from preneoplasia to lung adenocarcinoma (2019) (0)
Elevated PDGFRB gene copy number gain as prognostic in resected malignant pleural mesothelioma. (2012) (0)
Genomic heterogeneity of lung cancers and its potential clinical implications. (2015) (0)
1928P Pathologic assessment following neoadjuvant immunotherapy or chemotherapy demonstrates similar patterns in non-small cell lung cancer (NSCLC) (2018) (0)
A weight-adjusted Peto’s test when cause of death is not assigned (2005) (0)
Deep learning signature from chest CT and association with immunotherapy outcomes in EGFR/ALK-negative NSCLC. (2022) (0)
PET Metabolic Tumor Response by PERCIST Reliably Predicts Local Regional Control in Locally Advanced Non-Small Cell Lung Cancer After Concurrent Chemoradiation Therapy With Erlotinib (2015) (0)
Chapter 59 – Cancer Chemoprevention (2008) (0)
A Collection of Statistical Methods for Precision Oncology. (2019) (0)
Induction chemotherapy with and without erlotinib in patients with oral cavity squamous cell carcinomas (OCSCCs) amenable for surgical resection. (2019) (0)
PI3K/AKT/mTOR genomic alterations in 94 patients with metastatic breast cancer in the phase I clinic at MD Anderson: Prevalence and association with response. (2014) (0)
Immunogenomic profiling of lung adenocarcinoma reveals high-grade growth patterns are associated with an immunogenic tumor microenvironment (2022) (0)
A Second Order Semiparametric Method for Survival Analysis , with Application to an AIDS Clinical Trial Study (2016) (0)
Bayesian Adaptive Randomization and Trial Monitoring with Predictive Probability for Time-to-Event Endpoint (2017) (0)
Implication of p16INK4a and RASSF1A promoter methylation in patients with resectable non-small cell lung cancer (NSCLC). (2004) (0)
Lessons from the Failure to Complete a Trial of Denosumab in Women With a Pathogenic BRCA1/2 Variant Scheduling Risk-Reducing Salpingo-Oophorectomy. (2022) (0)
High Capacity cDNA RT-kit and TaqMan (2018) (0)
Predictive Biomarkers and Personalized Medicine Comprehensive Biomarker Analysis and Final Ef fi cacy Results of Sorafenib in the BATTLE Trial (2013) (0)
58 – Cancer Chemoprevention (2015) (0)
TCR repertoire sequencing of 254 resected non-small cell lung cancers to reveal TCR clonality in normal tissues compared to tumor tissues. (2017) (0)
bcl-2 and p 53 Expression in Resectable Pancreatic Adenocarcinomas : Association with Clinical Outcome 1 (2005) (0)
Real-world Studies Link NSAID Use to Improved Overall Lung Cancer Survival (2022) (0)
Abstract 5638: Preclinical evidence supporting cotargeting insulin-like growth factor receptor (IGF-1R) and Src in non-small cell lung cancer. (2013) (0)
Automated Detection Improves Identification of Oligometastatic Disease and Prevention of Missing Metastases During Local Ablative Therapies. (2021) (0)
Phase II Trials with Anticancer Agents (2011) (0)
Companion Diagnostics & Cancer Biomarkers Elevated Cyclin D 1 Expression Is Predictive for a Bene fi t from TPF Induction Chemotherapy in Oral Squamous Cell Carcinoma Patients with Advanced Nodal Disease (2013) (0)
Testing hypotheses about medical test accuracy: considerations for design and inference (2015) (0)
Do surrogate marker results transform to clinical prevention success (2006) (0)
Chronic exposure to waterpipe smoke elicits immunomodulatory and carcinogenic effects in the lung. (2022) (0)
Intensity-Modulated Proton Therapy ( IMPT ) versus Intensity-Modulated Photon Radiotherapy ( IMRT ) for Oropharyngeal Cancer : First Comparative Results of Patient-Reported Outcomes (2017) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With J. Jack Lee?

J. Jack Lee is affiliated with the following schools: